Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | SRC | P12931 | 16/20 | 1.00 |
| ▸ | ABL1 | P00519 | 15/20 | 1.00 |
| ▸ | ABL2 | P42684 | 15/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 0.79 |
| ▸ | KDR | P35968 | 3/20 | 0.79 |
| ▸ | TEK | Q02763 | 2/20 | 0.79 |
| ▸ | IGF1R | P08069 | 3/20 | 0.72 |
| ▸ | LYN | P07948 | 2/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | INSR | P06213 | 1/20 | 0.72 |
| ▸ | NPM1 | P06748 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | MET | P08581 | 1/20 | 0.72 |
| ▸ | ROS1 | P08922 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | KIT | P10721 | 1/20 | 0.72 |
| ▸ | BCR | P11274 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521878 | 0.99 | EGFR (0.98) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL7025438 | 0.92 | ABL1 (0.85) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL8098925 | 0.91 | SRC (0.89) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL7004447 | 0.88 | LCK (1.00) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL14040958 | 0.87 | SRC (1.00) | EGFRSRCABL1ABL2LCK | |
| Hydrochloric Acid SCHEMBL8099098 | 0.86 | SRC (0.98) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL8107295 | 0.86 | EGFR (0.86) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL7021384 | 0.86 | EGFR (1.00) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL7019158 | 0.85 | ABL1 (0.74) | EGFRSRCABL1ABL2LCK | |
| SCHEMBL7016766 | 0.84 | ABL1 (1.00) | EGFRSRCABL1ABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3641776-B1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) | 2023-10-18 | — | — | EP | disclosed |
| US-10934300-B2 | Atropisomerism for enhanced kinase inhibitor selectivity | SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200165258-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-28 | — | — | US | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934300-B2 | Atropisomerism for enhanced kinase inhibitor selectivity | MAP2K2, MAP2K3, MAP3K20 | EGFR 417/4885SRC 161/4885ABL1 157/4885 |
| US-20200165258-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | MAP2K2, MAP2K3, MAP3K20 | EGFR 417/4885SRC 161/4885ABL1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.